Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Stopped This study was terminated early due to response rates not meeting the anticipated minimum of 30%.
Conditions
- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- DRUG: Azacitidine
- BIOLOGICAL: Lirilumab
Sponsor
M.D. Anderson Cancer Center
Collaborators